Japan Tobacco, Inc.
JT Bldg. 2
About Japan Tobacco, Inc.
11 articles with Japan Tobacco, Inc.
Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan
Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan.
Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.
Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.
Keryx Biopharmaceuticals Licenses Rights to Japan Tobacco; Torii Pharmaceutical Co. to Pay up to $100 Million